健帆生物: 关于健帆转债回售结果的公告

Core Viewpoint - The company announced the results of the convertible bond repurchase, indicating minimal impact on its financial status and operations [1][2]. Group 1: Announcement of Convertible Bond Repurchase - The company disclosed the repurchase of its convertible bonds ("健帆转债") in accordance with relevant regulations, allowing bondholders to sell their bonds back to the company at a price of RMB 100.227 per bond during the specified period from August 8 to August 14, 2025 [1]. - Multiple announcements regarding the repurchase were made, including the initial notice and several reminders to bondholders [1]. Group 2: Results and Impact of the Repurchase - The effective number of bonds repurchased was 48, totaling a repurchase amount of RMB 4,810.89, which includes interest and tax [2]. - The repurchase will not significantly affect the company's financial condition, capital structure, operating results, or cash flow, and will not impair its debt servicing ability or ongoing operations [2]. Group 3: Subsequent Matters - Unredeemed convertible bonds will continue to be traded on the Shenzhen Stock Exchange [2].